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Purpose: To evaluate the profile of in vitro susceptibility of yeasts isolated from cases 
of primary and espisodic vulvovaginitis to two antifungal agents. Methods: 40 Can-
dida isolates from episodes of vulvovaginal candidiasis were identified by classic me-
thodologies. The susceptibility testing of the in vitro fluconazole and ketoconazole 
activity against the isolates was accessed by E-test. Results: C. albicans was the most 
common species identified in 70% of the occurrences followed by C. glabrata (20%), 
C. tropicalis (7.5%), and C. guilliermondii (2.5%). In the susceptibility profile to an-
tifungal agents, 12.5% and 16.7% of the isolates obtained from primary and episodic 
vulvovaginal candidiasis were resistant to fluconazole, respectively. To ketoconazole, 
we found that 6.25% and 12.5% of the isolates respectively from primary vulvovagin-
al candidiasis (PVVC) and episodic vulvovaginal candidiasis (EVVC) had high MIC 
values. Conclusions: E-test is a reliable method for the susceptibility testing of Can-
dida spp. due to its simplicity, reproducibility, and lack of specialized equipment. Re-
sistant strains and non-albicans species were verified more in cases of EVVC than in 
PVVC. Clinical and mycological cure of patients with episodic vulvovaginal candi-
diasis or complicated cases occurred after prolonged treatment and sometimes with 
multiple antifungals use. 
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Vulvovaginal candidiasis (VVC) is classified as primary or non-complicated when ma-
nifested by sporadic or infrequent episodes with mild or moderate symptoms in healthy 
and non-pregnant woman, while complicated episodic and recurrent cases of Candida 
vulvovaginitis have more severe symptoms and signs with high frequency of resistant 
yeast species [1] [2]. Changes of pH, vaginal microbiota, and the endogenous host fac-
tors may trigger the disease [1]-[4]. Candida albicans has been the most common caus-
al agent and non-albicans species have been increasingly identified [4]-[7]. The overall 
increase of resistant microorganisms and the consequent occurrence of refractory cases 
for treatments commonly used have been quicken for the interest in researches to de-
velopment of new antimicrobial drugs, therapeutic schemes and susceptibility tests [5] 
[8] [9].  
Azole substances have been used as the first-line of antifungal agents for treatment of 
VVC. However, the susceptibility obtained in vitro is not predictive of therapeutic suc-
cess [10] [11]. On the other hand, the resistance could be a factor involved in inefficacy 
of antifungal drug therapy mainly in refractory cases [5] [12] [13].     
E-test has been considered as an alternative to the reference broth microdilution 
method (CLSI) for its practicability and reproducibility [14]-[16]. It is easy, fast, and 
can be used by the gynecologist for increased reliability of prescription medication, espe-
cially in more complicated cases [15]-[17]. Comparison between the E-Test and micro-
dilution showed high reliable correlation to fluconazole, voriconazole and caspofungin 
[18]. 
Due to the importance of vulvovaginal candidiasis at gynecological practice and the 
few Brazilian works on the fungal susceptibility testing of the strains isolated from 
VVC, the aim of this investigation was to evaluate the in vitro susceptibility to flucona-
zole and ketoconazole of Candida spp. isolated from primary and episodic cases as-
sessed by E-Test in São Paulo (Brazil).  
2. Material and Methods 
In a prospective study conducted during two years, evaluated in private and public gy-
necological services in the greater São Paulo city (São Paulo State, Brazil), 562 women 
between the ages 18 and 65 years were followed up, and 168 of them with clinical suspi-
cion of VVC were carefully investigated. Itching, discharge, erythema, dysuria, vulvar 
burning, and pain were the signs and symptoms analyzed.  
According to the intensity, an arbitrary punctuation was attributed for each manife- 
station following the score: zero to three—was not considered; four to six-mild; seven 
to 13-moderate; 14 to 18-severe. The criteria of inclusion in this investigation were: pa-
tients with age range from 18 to 65 years, with positive cultures for Candida spp., in-
tensity of signs and symptoms equal to greater than four, not pregnant, without any 
immunocomprising conditions. After the exclusion of women with diabetes mellitus, 
immuno-deficiency as HIV positive, in use of vaginal douches, spermicides, or intra-
uterine device (IUD), and on steroid, hormone or antibiotic therapy, 40 patients with 
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clinical and laboratory diagnosis of VVC were selected; 16 patients with primary vul-
vovaginal candidiasis (PVVC) as group A and 24 with episodic vulvovaginal candidiasis 
(EVVC) as group B. Topical or systemic azole, or the combination of both was used for 
treatment and the patient evolution was carefully monitored.  
The vaginal secretions were collected with non-lubricated speculum from the ecto-
cervix and posterior vaginal fornix, using moistened swab in sterile saline solution. This 
procedure was performed after science and signing of agreement each patient. The 
study was approved by the Ethics Committee of the Federal University of São Paulo 
under n˚ 1719/05 and conducted according to the Helsinki Declaration revised in 2008. 
One part of the samples was submitted to direct microscopy with KOH 20% more 
ink Parker (three to one) and smears were stained by Gram method. The other part was 
seeded on Sabouraud dextrose agar media supplemented with chloramphenicol (100 
mg/ml) and CHROMagar Candida for screening of presumptive species. The yeast 
identification was performed according to morphological, biochemical and physio- 
logical characterization of the isolated species. Candida albicans identification was con-
firmed by the presence of chlamidoconidia in cornmeal agar tween 80, production 
germ tube at 37˚C in serum and growth in hypertonic media at 42˚C.  
The susceptibility test of the isolates was performed by kit E-Test (AB Biodisk, Solna, 
Sweden) and the protocol followed the manufacturer’s instructions. The assay medium 
RPMI 1640 agar supplemented with MOPS, L-glutamine, and glucose (HiMedia Labo- 
ratories, Bombai, India) was prepared and distributed in 90 mm-diameter Petri-dishes. 
Candida isolates were previously cultivated for 24 h on Sabouraud dextrose agar and in-
oculated on tubes with 3 mL of sterile saline, turbidity of 0.5 McFarland scale and then 
seed with sterile swabs on the surface of the medium. After 15 min of drying at room 
temperature, the E-Test strings of fluconazole and ketoconazole were placed on the agar 
surface and the plates were incubated at 37˚C. The readings for the minimal inhibitory 
concentration (MIC) for the antifungal drugs were performed after 24 and 48 h of incu-
bation. Interpretation of the results for was based on the values of MIC recommended by 
documents CLSI M27 A2, CLSI M27 A3 and CLSI M27 S4 [19]-[21]. For the ketocona-
zole there are not established breakpoints. The reference strain Candida parapsilosis ATCC 
22019 was included for quality control. All experiments were performed in triplicate.  
The Chi-Square tests were used in order to correlate the intensity of clinical forms of 
PVVC and EVVC and the in vitro susceptibility profile to fluconazole and ketoconazole. 
3. Results 
In this investigation, we analyzed 40 strains of Candida species, 26 from PVVC and 24 
from EVVC. Candida albicans (70%) was the prevalent species, followed by C. glabrata 
(20%), C. tropicalis (7.5%) and C. guilliermondii (1.5%). The relationship of Candida 
species isolated from patients with PVVC and EVVC are described in Table 1. Candida 
glabrata was the prevalent non-albicans species isolated mainly in EVVC.  
The intensity of signs and symptoms according to the species of Candida are represented 
in Table 2. The major number of patients (72.5%) presented a moderate degree of 
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C. albicans 13 (32.25) 15 (37.5) 28 (70) 
C. glabrata 1 (2.5) 7 (17.5) 8 (20) 
C. trocipalis 2 (5) 1 (2.5) 3 (7.5) 
C. guilliermondii - 1 (2.5) 1 (2.5) 
VVC = vulvovaginal candidiasis, PVVC = primary VVC , EVVC = episodic VVC. 
 










C. albicans 8 (20) 20 (50) - 28 (70) 
C. glabrata 2 (5) 6 (15) - 8 (20) 
C. trocipalis - 2 (5) 1 (2.5) 3 (7.5) 
C. guilliermondii - 1 (2.5) - 1 (2.5) 
Total 10 (25) 29 (72.5) 1 (2.5) 40 (100) 
 
VVC. Mild symptoms and signs were observed in 10 women (25%) and a severe pres-
entation occurred only in one patient (2.5%). We do not observed correlation between 
symptoms and signs, manifestations type (PVVC and EVVC) and identified species. 
The most common age ranging was verified in patients from 18 to 32 years old.  
In PVVC, only two isolates (one C. albicans and one C. glabrata, 12.5%) of 16 isolates 
showed resistance to fluconazole (Table 3). In EVVC, five isolates (one C. albicans and 
4 C. glabrata) showed high MICs for fluconazole, and 4 isolates were SDD (3 C. glabra-
ta and 1 C. guilliermondii).  
In relation to ketoconazole, four isolates of C. glabrata (one from PVVC and three 
from EVVC, respectively 6.25% and 12.5%), two C. albicans strains (from PVVC and 
EVVC), two C. tropicalis strains (from PVVC), and the single-isolate C. guilliermondii 
showed high MICs > 16 µg/ml. Five isolates, C. glabrata (4) and C. albicans (1) have 
proved to be both resistant to fluconazole and high MICs values to ketoconazole. 
Trailing phenomenon was recorded in 25% of isolates.  
In vitro susceptibility profile of the isolates to antifungal fluconazole and ketocona-
zole showed no significant clinical correlation with PVVC or EVVC and signs and 
symptoms in VVC. 
In PVVC (group A) there was clinical and mycological cure after the first treatment 
with fluconazole 150 mg orally once weekly for two weeks. In this group, two samples 
(12.5%) were resistant to antifungal, one C. albicans isolate (6.25%) and one C. glabrata 
isolate (6.25%). The isolates obtained from the other 14 patients, C. albicans (12) and C. 
tropicalis (2) were susceptibility to fluconazole. 
In EVVC (group B), 16 patients achieved clinical and mycological cures after the 
second treatment with fluconazole 150 mg orally once weekly for 3 weeks. In six pa-
tients, clinical and mycological cure occurred after the third treatment with ketocona-
zole orally at 400 mg daily for 14 days. And in the other two patients in this group, healing  
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Table 3. In vitro susceptibility profile to fluconazole of Candida species isolated from 40 cases of 









C. albicans 12/15 0/0 1/0 28 
C. glabrata 0/0 0/3 1/4 8 
C. trocipalis 2/1 0/0 0/0 3 
C. guilliermondii 0/0 0/1 0/0 1 
Total 14/16 0/4 2/4 40 
VVC = vulvovaginal candidiasis, S = susceptible, SDD = susceptible-dose dependent, R = resistant. 
 
was given after the fourth treatment with fluconazole 150 mg orally weekly, for 4 weeks 
up to 6 weeks. We emphasize the occurrence of a higher strength and high MIC ob-
served for C. glabrata, including a little therapeutic response especially in EVVC. 
4. Discussion 
Vulvovaginal candidiasis is an insidious infection that affects a large proportion of fe-
male patients, most frequently in the reproductive age [1]-[4]. The distinction between 
bacterial and fungal vaginitis in relation to symptoms and etiological agent contributes 
to the therapeutic success [22]. Although C. albicans is the most frequently isolated 
species, other species have been found as infectious agents such as C. glabrata, C. trop-
icalis and C. guillermondii [5] [6] [10] [23]. In our study, C. albicans and C. glabrata 
were the two most prevalent species. The C. glabrata strains were more resistant to an-
tifungal agents commonly used in clinical practice. The resistant species were also fre-
quently involved in relapse after treatment. The relapses were associated with prolonga-
tion of time action and consequently higher dosage of the drugs, and sometimes with 
the use of more than one antifungal during the treatment for VVC. 
A recent study using the microdilution methods and disk diffusion resistance rec-
orded Candida spp. emphasizes the need for standardization of methods that allow a 
better correlation between the resistance patterns and clinical manifestations [24]. Flu-
conazole resistance in species of C. albicans has not been shown as very common [10] 
[23] [25]-[29] on average less than 10% of the VVC isolated, while in C. glabatra resis-
tant or susceptible-dose dependent occurring frequently around or more than 50% of 
the strains [5] [30]-[34]. In this investigation, 3.5% and 62.5% of the isolates of C. albi-
cans and C. glabrata, respectively, proved to be resistant to fluconazole. Most yeast iso-
lates from patients with EVVC, similar to those of the PVVC, in our research, were 
susceptible to fluconazole and ketoconazole, except C. glabrata. A study conducted for 
8 years in China, with 2.204 isolates of Candida spp revealed prevalence of C. albicans, 
but an increase of non-albicans species such as C. glabrata over the years and antifungal 
resistance [35]. Unlike our study, in other Chinese research, high rate of resistant iso-
lates for the ketoconazole was detected in 186 Candida strains from patients with VVC 
[36], observing resistance route 27.7% in C. albicans strains and 56.2% in non-albicans 




Cross-resistance between azole antifungals such as fluconazole and ketoconazole is 
not uncommon fact [28] [32] [36] [37]. In our study, five (12.5%) isolates were resistant 
to fluconazole also showed great MICs values to ketoconazole. The selective pressure 
generated by the previous use of these two antifungal agents in cases of relapse is possi-
bly correlated to the emergence of resistant strains isolated [31] [32] [38]. Fluconazole 
is inducing agent to selection of C. albicans with homozygous profile to MTL gene fast 
mode and high-frequency [39]. Treatment failure of CVV, in case of relapse or refrac-
tory, may also be associated with decreased susceptibility to the antifungal agent [28] 
[40]. Our investigation found susceptibility dose dependent (SDD) of C. guilliermondii 
to fluconazole and ketoconazole. This isolate was from second episode. This is consis-
tent with other studies that shown C. guilliermondii as an emerging yeast with reduced 
susceptibility to antifungal agents [6] [23] [24] [41] [42]. 
Finally, we denote that susceptibility testing to antifungal agents of the isolated yeast 
of VVC, especially those of clinical significance, is important for detecting resistant mi-
croorganisms and may contribute to medical management and consequent therapeutic 
success, especially in episodic or complicated fungal vulvovaginitis. The intrinsic resis-
tance of many strains and the antifungal drugs used for a long term or inappropriate 
treatment can leave to resistant-yeast selection among the fungal species [33]. On the 
other hand, antifungals used for a long period can leave susceptible or susceptible dose- 
dependent microorganisms to become more resistant to multiple drugs [11]. The use of 
E-test method is interesting as a screening method due to its practicality and a pre-
sumptive result of degree of susceptibility. Isolates that showed elevated MIC for the 
two tested antifungal agents were mainly C. glabrata, and much lower percentages of C. 
albicans, the two species most commonly found in this study. Further investigations 
with more VVC cases are necessary in order to analyze other factors related to the host 
and to fungal agents that will add to knowledge of the pathogenesis and maintenance of 
CVV.  
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